UNSPSC 51182439: Teriparatide recombinant human

This classification denotes a recombinant parathyroid hormone with the molecular formula C181H291N55O51S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 10T9CSU89I, chemically known as l-phenylalanine, l-seryl-l-valyl-l-seryl-l-alpha-glutamyl-l-isoleucyl-l-glutaminyl-l-leucyl-l-methionyl-l-histidyl-l-asparaginyl-l-leucylglycyl-l-lysyl-l-histidyl-l-leucyl-l-asparaginyl-l-seryl-l-methionyl-l-alpha-glutamyl-l-arginyl-l-valyl-l-alpha-glutamyl-l-tryptophyl-l-leucyl-l-arginyl-l-lysyl-l-lysyl-l-leucyl-l-glutaminyl-l-alpha-aspartyl-l-valyl-l-histidyl-l-asparaginyl- but more generally known as teriparatide, which bears US NIH Compound Identifier 16129682.

UNSPSC 51182439 Teriparatide recombinant human is a Commodity code covering a specific pharmaceutical product used to treat osteoporosis and related bone disorders in state and local health systems. Teriparatide, a recombinant human parathyroid hormone analog, is procured by state Medicaid agencies, county health departments, municipal hospital systems, and other public health entities as part of formulary management and direct patient care delivery. The drug is typically acquired through state pharmaceutical cooperative purchasing vehicles, group purchasing organization contracts, or direct RFQ processes; procurement is often tied to Medicaid reimbursement coverage determinations and bulk purchasing agreements that negotiate unit pricing across multiple doses and delivery schedules.

The source provided contains no recent opportunities or issuing-body activity data under this code. Without posted state and local solicitations, geographic concentration, repeat buyers, or representative RFPs or RFQs to reference, no concrete market characterization or procurement timing can be drawn.